Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.
Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
Concomitant medicinal product levels increased or decreased
1-Adrenoreceptor Alfuzosin Increased plasma concentrations of alfuzosin
Antagonist which may lead to severe hypotension (see
section 4.5).
Analgesics Pethidine, Increased plasma concentrations of
propoxyphene norpethidine and propoxyphene. Thereby,
increasing the risk of serious respiratory
depression or haematologic abnormalities, or
other serious adverse effects from these agents.
Antianginal Ranolazine Increased plasma concentrations of ranolazine
which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Anticancer Neratinib Increased plasma concentrations of neratinib
which may increase the potential for serious
and/or life-threatening reactions including
hepatotoxicity (see section 4.5).
Venetoclax Increased plasma concentrations of venetoclax.
Increased risk of tumor lysis syndrome at the
dose initiation and during the dose-titration
phase (see section 4.5).
Antiarrhythmics Amiodarone, bepridil, Increased plasma concentrations of amiodarone,
dronedarone, bepridil, dronedarone, encainide, flecanide,
encainide, flecanide, propafenone, quinidine. Thereby, increasing the
propafenone, quinidine risk of arrhythmias or other serious adverse
reactions from these agents.
Antibiotic Fusidic Acid Increased plasma concentrations of fusidic acid
and ritonavir.
Anti-gout Colchicine Potential for serious and/or life-threatening
reactions in patients with renal and/or hepatic
impairment (see sections 4.4 and 4.5).
Antihistamines Astemizole, Increased plasma concentrations of astemizole
terfenadine and terfenadine. Thereby, increasing the risk of
serious arrhythmias from these agents.
Antipsychotics/ Lurasidone Increased plasma concentrations of lurasidone
Neuroleptics which may increase the potential for serious
and/or life-threatening reactions (see section
4.5).
Clozapine, pimozide Increased plasma concentrations of clozapine
and pimozide. Thereby, increasing the risk of
serious haematologic abnormalities, or other
serious adverse effects from these agents.
Quetiapine Increased plasma concentrations of quetiapine
which may lead to coma. The concomitant
administration with quetiapine is
contraindicated (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Concomitant medicinal product levels increased
Alpha1-adrenoreceptor Alfuzosin Increased plasma concentrations of
antagonist alfuzosin which may lead to severe
hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor lysis
syndrome at the dose initiation and
during the ramp-up phase (see section
4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients with
renal and/or hepatic impairment (see
sections 4.4 and 4.5).
Antihistamines Astemizole, terfenadine Increased plasma concentrations of
astemizole and terfenadine. Thereby,
increasing the risk of serious
arrhythmias from these agents (see
section 4.5).
Antipsychotics/ Lurasidone Increased plasma concentrations of
Neuroleptics lurasidone which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Pimozide Increased plasma concentrations of
pimozide. Thereby, increasing the risk
of serious haematologic abnormalities,
or other serious adverse effects from this
agent (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Concomitant medicinal product levels increased
Alpha1- Alfuzosin Increased plasma concentrations of
adrenoreceptor alfuzosin which may lead to severe
antagonist hypotension. The concomitant
administration with alfuzosin is
contraindicated (see section 4.5).
Antianginal Ranolazine Increased plasma concentrations of
ranolazine which may increase the
potential for serious and/or life-
threatening reactions (see section 4.5).
Antiarrhythmics Amiodarone, dronedarone Increased plasma concentrations of
amiodarone and dronedarone. Thereby,
increasing the risk of arrhythmias or
other serious adverse reactions (see
section 4.5).
Antibiotic Fusidic Acid Increased plasma concentrations of
fusidic acid. The concomitant
administration with fusidic acid is
contraindicated in dermatological
infections (see section 4.5).
Anticancer Neratinib Increased plasma concentrations of
neratinib which may increase the
potential for serious and/or
life-threatening reactions (see section
4.5).
Venetoclax Increased plasma concentrations of
venetoclax. Increased risk of tumor
lysis syndrome at the dose initiation
and during the ramp-up phase (see
section 4.5).
Anti-gout Colchicine Increased plasma concentrations of
colchicine. Potential for serious and/or
life-threatening reactions in patients
with renal and/or hepatic impairment
(see sections 4.4 and 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 9293fe9ecfe32956533c5b772cc23612b4a6e3a500aeb3b328481fd78b786272 · Zeichen 583–3923 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.